[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633744":3},{"organization":4,"armGroups":7,"interventions":41,"overallOfficials":11,"centralContacts":66,"locations":72,"responsibleParty":90,"collaborators":11,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":11,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":11,"enrollmentInfo":101,"targetDuration":11,"studyType":104,"phases":105,"briefSummary":108,"conditions":109,"keywords":11,"overallStatus":112,"whyStopped":11,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Dartsbio Pharmaceuticals Ltd.","INDUSTRY",[8,14,17,20,23,26,29,32,35,38],{"label":9,"type":10,"description":11,"interventionNames":12},"DS010 dose level 1","EXPERIMENTAL",null,[13],"Drug: DS010 injection",{"label":15,"type":10,"description":11,"interventionNames":16},"DS010 dose level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"DS010 dose level 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"DS010 dose level 4",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"DS010 dose level 5",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"DS010 dose level 6",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"DS010 expansion 1",[13],{"label":33,"type":10,"description":11,"interventionNames":34},"DS010 expansion 2",[13],{"label":36,"type":10,"description":11,"interventionNames":37},"DS010 expansion 3",[13],{"label":39,"type":10,"description":11,"interventionNames":40},"DS010 expansion 4",[13],[42,47,49,51,53,55,57,60,62,64],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":11},"DRUG","DS010 injection","Once every 3 weeks intravenously injection",[9],{"type":43,"name":44,"description":45,"armGroupLabels":48,"otherNames":11},[15],{"type":43,"name":44,"description":45,"armGroupLabels":50,"otherNames":11},[18],{"type":43,"name":44,"description":45,"armGroupLabels":52,"otherNames":11},[21],{"type":43,"name":44,"description":45,"armGroupLabels":54,"otherNames":11},[24],{"type":43,"name":44,"description":45,"armGroupLabels":56,"otherNames":11},[27],{"type":43,"name":44,"description":58,"armGroupLabels":59,"otherNames":11},"Once every 3 weeks or once every 4 weeks intravenously injection",[30],{"type":43,"name":44,"description":58,"armGroupLabels":61,"otherNames":11},[33],{"type":43,"name":44,"description":58,"armGroupLabels":63,"otherNames":11},[36],{"type":43,"name":44,"description":58,"armGroupLabels":65,"otherNames":11},[39],[67],{"name":68,"role":69,"phone":70,"phoneExt":11,"email":71},"Rock Xie","CONTACT","86-15805177049","xiez@dartsbio.com",[73],{"facility":74,"status":11,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":86},"Sun Yat-sen University Cancer Center","Guangzhou","Guangdong","510060","China","CN",{"type":81,"coordinates":82},"Point",[83,84],113.25,23.11667,{"lat":84,"lon":83},[87],{"name":88,"role":89,"phone":11,"phoneExt":11,"email":11},"Li Zhang, Professor","PRINCIPAL_INVESTIGATOR",{"type":91,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100633744","phase-1-study-of-the-safety-and-efficacy-of-ds010-in-patients-with-cancer-cachexia-100633744",false,"NCT07530666","Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia","Phase I\u002FII Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of DS010 in Patients With Cancer Cachexia","Key Inclusion Criteria:\n\n1. Subjects aged ≥ 18 years at screening;\n2. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures;\n3. Able to provide written informed consent;\n4. ECOG performance status score of 0, 1, or 2;\n5. Patients with histologically or cytologically confirmed malignant solid tumor;\n6. Cancer cachexia documented in medical records;\n\nKey Exclusion Criteria:\n\n1. History of hypersensitivity or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody or molecules composed of monoclonal antibody components;\n2. Presence of reversible decreased food intake, as determined by the investigator;\n3. Receiving tube feeding or parenteral nutrition (total or partial parenteral nutrition) at screening;\n4. Severe gastrointestinal disorders (including esophagitis, gastritis, malabsorption);\n5. Cachexia caused by other reasons;\n6. Currently participating in another investigational drug study, or receipt of another investigational product ;","ALL","18 Years",{"count":102,"type":103},58,"ESTIMATED","INTERVENTIONAL",[106,107],"PHASE1","PHASE2","A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia",[110,111],"Cancer","Cachexia","NOT_YET_RECRUITING","2026-04-08",{"date":115,"type":116},"2026-04-15","ACTUAL",{"date":118,"type":103},"2026-04-30",{"date":120,"type":103},"2028-04-30",{"name":5,"class":6},1]